XML 12 R2.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 1,973 $ 1,782
Trade receivables 5,108 5,822
Inventories 4,782 4,731
Prepaid expenses 969 899
Other current assets 438 468
Assets held for sale 162 92
Total current assets 13,431 13,794
Deferred income taxes 351 368
Other non-current assets 756 731
Property, plant and equipment, net 6,785 6,868
Operating lease right-of-use assets 517  
Identifiable intangible assets, net 13,191 14,005
Goodwill 24,822 24,917
Total assets 59,854 60,683
Current liabilities:    
Short-term debt 2,790 2,216
Sales reserves and allowances 6,200 6,711
Trade payables 1,763 1,853
Employee-related obligations 633 870
Accrued expenses 1,869 1,868
Other current liabilities 773 804
Total current liabilities 14,028 14,322
Long-term liabilities:    
Deferred income taxes 2,079 2,140
Other taxes and long-term liabilities 1,669 1,727
Senior notes and loans 25,834 26,700
Operating Lease Liabilities 424  
Total long-term liabilities 30,005 30,567
Commitments and contingencies, see note 16
Total liabilities 44,033 44,889
Teva shareholders' equity:    
Ordinary shares of NIS 0.10 par value per share; March 31, 2019 and December 31, 2018: authorized 2,495 million shares; issued 1,198 million shares and 1,196 million shares, respectively 56 56
Additional paid-in capital 27,234 27,210
Accumulated deficit (6,063) (5,958)
Accumulated other comprehensive loss (2,359) (2,459)
Treasury shares as of March 31, 2019 and December 31, 2018 — 107 million ordinary shares and 106 million ordinary shares, respectively (4,137) (4,142)
Stockholders' equity attributable to Teva shareholders 14,732 14,707
Non-controlling interests 1,089 1,087
Total equity 15,821 15,794
Total liabilities and equity $ 59,854 $ 60,683